Your browser is no longer supported. Please, upgrade your browser.
Settings
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E17.65 EPS (ttm)4.33 Insider Own0.30% Shs Outstand181.14M Perf Week-6.62%
Market Cap14.63B Forward P/E50.70 EPS next Y1.51 Insider Trans-9.39% Shs Float180.42M Perf Month-8.22%
Income852.00M PEG0.55 EPS next Q-0.05 Inst Own- Short Float6.22% Perf Quarter-3.96%
Sales1.86B P/S7.86 EPS this Y3200.00% Inst Trans0.92% Short Ratio7.45 Perf Half Y0.46%
Book/sh22.38 P/B3.41 EPS next Y2912.00% ROA2.30% Target Price110.70 Perf Year-21.17%
Cash/sh7.86 P/C9.72 EPS next 5Y32.16% ROE3.60% 52W Range68.25 - 131.95 Perf YTD-12.93%
Dividend- P/FCF- EPS past 5Y37.13% ROI21.70% 52W High-42.13% Beta0.59
Dividend %- Quick Ratio2.40 Sales past 5Y15.90% Gross Margin73.50% 52W Low11.87% ATR2.60
Employees3001 Current Ratio3.20 Sales Q/Q3.40% Oper. Margin3.20% RSI (14)34.48 Volatility3.78% 2.99%
OptionableYes Debt/Eq0.36 EPS Q/Q47.10% Profit Margin6.60% Rel Volume0.86 Prev Close76.09
ShortableYes LT Debt/Eq0.27 EarningsFeb 25 AMC Payout0.00% Avg Volume1.51M Price76.35
Recom2.10 SMA20-7.94% SMA50-9.90% SMA200-16.94% Volume1,327,123 Change0.34%
Mar-04-21Resumed Guggenheim Buy
Mar-01-21Upgrade Evercore ISI In-line → Outperform $90 → $100
Aug-20-20Downgrade William Blair Outperform → Mkt Perform
Aug-20-20Downgrade Citigroup Buy → Neutral $148 → $86
Aug-19-20Downgrade Stifel Buy → Hold $127 → $100
Aug-19-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-19-20Downgrade Evercore ISI Outperform → In-line
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $125
Jul-06-20Reiterated Citigroup Buy $105 → $148
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Jan-24-20Upgrade RBC Capital Mkts Sector Perform → Outperform $111 → $113
Nov-27-19Upgrade Barclays Equal Weight → Overweight $86 → $98
Nov-12-19Initiated SunTrust Buy $110
Oct-17-19Resumed BofA/Merrill Buy $90
May-23-19Resumed Citigroup Buy
Apr-09-19Resumed Raymond James Outperform
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18Initiated Wolfe Research Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $126
Mar-03-21 08:31AM  
Feb-26-21 10:50PM  
12:02PM  
09:16AM  
Feb-25-21 02:30PM  
Feb-24-21 10:09AM  
08:30AM  
Feb-18-21 04:01PM  
Feb-11-21 11:40AM  
Feb-06-21 01:52AM  
Jan-28-21 09:00AM  
Jan-26-21 11:40AM  
08:30AM  
Jan-22-21 07:55AM  
Jan-15-21 10:50PM  
Jan-12-21 09:24AM  
Jan-11-21 10:58AM  
10:14AM  
08:37AM  
08:11AM  
Jan-10-21 06:44PM  
Jan-07-21 11:40AM  
Jan-05-21 08:30AM  
Jan-04-21 08:42AM  
Dec-31-20 09:24AM  
Dec-21-20 08:29AM  
Dec-18-20 12:14PM  
Dec-17-20 04:21PM  
09:42AM  
Dec-14-20 01:38PM  
Dec-09-20 04:02PM  
Dec-05-20 11:32AM  
Dec-01-20 08:30AM  
Nov-24-20 03:35PM  
03:00PM  
11:39AM  
10:15AM  
10:00AM  
09:53AM  
09:13AM  
06:20AM  
Nov-23-20 10:50PM  
05:40PM  
04:10PM  
01:27PM  
12:00PM  
12:00PM  
11:00AM  
11:00AM  
10:15AM  
09:39AM  
06:32AM  
Nov-22-20 10:50PM  
01:00PM  
Nov-21-20 07:00AM  
Nov-20-20 10:50PM  
07:50PM  
07:09PM  
01:00PM  
01:00PM  
11:30AM  
11:20AM  
11:00AM  
09:33AM  
08:00AM  
Nov-19-20 06:09PM  
04:40PM  
04:37PM  
01:57PM  
12:30PM  
12:15PM  
11:08AM  
11:00AM  
10:30AM  
09:49AM  
06:20AM  
Nov-18-20 11:18PM  
10:50PM  
03:28PM  
02:00PM  
11:30AM  
11:00AM  
06:20AM  
Nov-17-20 10:50PM  
02:58PM  
01:30PM  
12:30PM  
11:45AM  
11:00AM  
08:29AM  
06:20AM  
Nov-16-20 10:50PM  
03:35PM  
02:45PM  
12:00PM  
11:08AM  
11:00AM  
06:20AM  
02:15AM  
Nov-15-20 11:00AM  
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerFeb 19Option Exercise26.497,000185,430302,552Feb 22 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 19Sale83.587,000585,060295,552Feb 22 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 18Option Exercise26.497,000185,430302,552Feb 19 09:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 18Sale85.087,000595,560295,552Feb 19 09:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 17Option Exercise26.498,000211,920303,552Feb 18 09:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 17Sale84.548,000676,320295,552Feb 18 09:45 PM
LAWLIS V BRYANDirectorFeb 16Option Exercise26.497,500198,67526,350Feb 18 06:43 PM
LAWLIS V BRYANDirectorFeb 16Sale87.417,500655,57518,850Feb 18 06:43 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 29Option Exercise26.498,334220,768303,886Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 29Sale82.678,334688,972295,552Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 28Option Exercise26.498,333220,741303,885Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 28Sale82.918,333690,889295,552Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 27Option Exercise26.498,333220,741303,885Jan 28 07:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 27Sale85.498,333712,388295,552Jan 28 07:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Sale88.181,500132,270295,552Dec 30 08:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Sale88.771,500133,155297,052Dec 30 08:02 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerOct 14Sale79.912,121169,48961,281Oct 15 07:17 PM
HERON ELAINE JDirectorOct 07Option Exercise26.4915,000397,35066,968Oct 08 08:35 PM
PYOTT DAVID E IDirectorAug 31Buy78.2612,8001,001,71530,740Sep 01 09:44 PM
GREY MICHAEL GDirectorAug 03Option Exercise26.492,50066,22545,340Aug 05 06:56 PM
GREY MICHAEL GDirectorAug 03Sale120.352,500300,87542,840Aug 05 06:56 PM
FUCHS HENRY JPresident, Worldwide R&DJul 20Option Exercise65.97126,3898,337,656229,384Jul 22 05:32 PM
FUCHS HENRY JPresident, Worldwide R&DJul 20Sale130.00126,38916,430,570102,995Jul 22 05:32 PM
FUCHS HENRY JPresident, Worldwide R&DJul 13Option Exercise65.9723,0111,518,094126,006Jul 15 09:32 PM
FUCHS HENRY JPresident, Worldwide R&DJul 13Sale130.0023,0112,991,430102,995Jul 15 09:32 PM
Dere Willard HDirectorJun 26Sale123.614,430547,59213,290Jun 30 02:11 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 19Option Exercise63.1015,000946,50078,402Jun 23 07:24 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 19Sale124.0015,0001,860,00063,402Jun 23 07:24 PM
LAWLIS V BRYANDirectorJun 05Sale107.464,430476,04818,850Jun 09 06:04 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Option Exercise21.5120,000430,200318,552May 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Sale91.7220,0001,834,400298,552May 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 04Option Exercise21.515,000107,550303,552May 05 07:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 04Sale88.005,000440,000298,552May 05 07:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Option Exercise21.514,00086,040302,552May 05 07:22 PM
Davis George EricEVP, General CounselMay 01Sale89.3812,5041,117,60865,677May 04 09:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale89.384,000357,520298,552May 05 07:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 28Option Exercise21.5120,000430,200318,213Apr 29 07:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 28Sale97.5820,0001,951,600298,213Apr 29 07:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Option Exercise21.5120,000430,200318,213Apr 29 07:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Sale97.7320,0001,954,600298,213Apr 29 07:40 PM
FUCHS HENRY JPresident, Worldwide R&DApr 24Sale95.8820,0001,917,617102,656Apr 28 02:37 PM
FUCHS HENRY JPresident, Worldwide R&DApr 20Sale90.0017,2131,549,170122,656Apr 22 05:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 09Option Exercise21.5110,000215,100308,213Apr 13 06:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 09Sale79.0610,000790,600298,213Apr 13 06:24 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 08Sale79.982,407192,51263,064Apr 09 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 07Option Exercise26.491,00026,490298,213Apr 08 08:54 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 01Sale82.001,537126,03465,471Apr 02 08:39 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 25Sale78.471,618126,96467,008Mar 26 08:34 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 24Sale74.362,041151,76968,626Mar 26 08:34 PM
LAWLIS V BRYANDirectorMar 17Option Exercise21.513,75080,66222,730Mar 18 08:46 PM
LAWLIS V BRYANDirectorMar 17Sale75.393,750282,71218,980Mar 18 08:46 PM
LAWLIS V BRYANDirectorMar 16Sale76.524,610352,75718,980Mar 18 08:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise21.5110,000215,100306,443Mar 11 09:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale89.5210,000895,200296,443Mar 11 09:01 PM